Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Labeling “Highlights” To Depend On Data In Relation To Clinical Setting

Executive Summary

Information to be included in the new Highlights of Prescribing Information section of professional labeling will be determined by the clinical setting in which the drug is used, FDA said

You may also be interested in...

REMS Communications Need FDA Logo To Boost Doctors’ Attention, Advisors Say

Risk Communication Advisory Committee suggests that adding the agency imprimatur to REMS materials may help distinguish it from promotional mail and ensure providers read the communications.

PhRMA's Web Search Solution: Add Icon Or Generic Risk Statement In Results

In run-up to FDA's meeting on the internet and social media, PhRMA makes its pitch to restore branded sponsored search engine results.

Draft Guidance Explains Inclusion Of Pharmacologic Class In New Labeling

FDA's standards for an "established" pharmacologic class are that the agency has determined the class is both scientifically valid and clinically meaningful, according to a draft guidance released May 15

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts